Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17201385 | 1.00 | ALDH1A1 (0.76) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL29675228 | 0.93 | ALDH1A1 (0.86) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL2469546 | 0.93 | ALDH1A1 (0.86) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL5521157 | 0.88 | ALDH1A1 (0.78) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL18829414 | 0.86 | ALDH1A1 (1.00) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL6244724 | 0.86 | ALDH1A1 (0.93) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL13841230 | 0.85 | ALDH1A1 (0.73) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL25306721 | 0.85 | ALDH1A1 (0.68) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL25263942 | 0.85 | ALDH1A1 (0.68) | ALDH1A1USP2HPGDNPSR1MC4R | |
| SCHEMBL25310521 | 0.85 | ALDH1A1 (0.68) | ALDH1A1USP2HPGDNPSR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2931707-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| CN-104968646-A | Enhancer of Zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC | 2015-10-07 | — | — | CN | disclosed |
| WO-2014107277-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-07-10 | — | — | WO | disclosed |
| EP-0813533-A4 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP INC (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5942520-A | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines | CELL PATHWAYS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0813533-A1 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996028446-A1 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5488055-A | ADMINISTERING GMP HOSPHODIESTERASE INHIBITORS FOR TREATMENT OF CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | SANOFI WINTHROP INC. (US) | 1996-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | ALDH1A1 2517/4885USP2 1486/4885HPGD 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.